These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 12800792)
1. Hematopoietic stem cell transplantation for non-Hodgkin's lymphoma. Holmberg LA; Stewart FM Oncology (Williston Park); 2003 May; 17(5):627-32, 635, 640; discussion 640-2. PubMed ID: 12800792 [TBL] [Abstract][Full Text] [Related]
2. Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation--The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. Bierman PJ; Sweetenham JW; Loberiza FR; Taghipour G; Lazarus HM; Rizzo JD; Schmitz N; van Besien K; Vose JM; Horowitz M; Goldstone A; J Clin Oncol; 2003 Oct; 21(20):3744-53. PubMed ID: 12963703 [TBL] [Abstract][Full Text] [Related]
3. High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma. Law LY; Horning SJ; Wong RM; Johnston LJ; Laport GG; Lowsky R; Shizuru JA; Blume KG; Negrin RS; Stockerl-Goldstein KE Biol Blood Marrow Transplant; 2006 Jul; 12(7):703-11. PubMed ID: 16785059 [TBL] [Abstract][Full Text] [Related]
4. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma. Nagler A; Slavin S; Varadi G; Naparstek E; Samuel S; Or R Bone Marrow Transplant; 2000 May; 25(10):1021-8. PubMed ID: 10828860 [TBL] [Abstract][Full Text] [Related]
5. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Peniket AJ; Ruiz de Elvira MC; Taghipour G; Cordonnier C; Gluckman E; de Witte T; Santini G; Blaise D; Greinix H; Ferrant A; Cornelissen J; Schmitz N; Goldstone AH; Bone Marrow Transplant; 2003 Apr; 31(8):667-78. PubMed ID: 12692607 [TBL] [Abstract][Full Text] [Related]
6. Indications and relative indications for stem cell transplantation in non-Hodgkin's lymphoma. Stewart FM Leukemia; 1993 Jul; 7(7):1091-4. PubMed ID: 8100601 [TBL] [Abstract][Full Text] [Related]
7. Long-term outcomes of autologous stem cell transplantation for follicular non-Hodgkin lymphoma: effect of histological grade and Follicular International Prognostic Index. Vose JM; Bierman PJ; Loberiza FR; Lynch JC; Bociek GR; Weisenburger DD; Armitage JO Biol Blood Marrow Transplant; 2008 Jan; 14(1):36-42. PubMed ID: 18158959 [TBL] [Abstract][Full Text] [Related]
8. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Petersen SL Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527 [TBL] [Abstract][Full Text] [Related]
9. Estimating late adverse events using competing risks after autologous stem-cell transplantation in aggressive non-Hodgkin lymphoma patients. Ruiz-Soto R; Sergent G; Gisselbrecht C; Larghero J; Ertault M; Hennequin C; Manson J; de Kerviler E; Briere J; Mounier N Cancer; 2005 Dec; 104(12):2735-42. PubMed ID: 16284986 [TBL] [Abstract][Full Text] [Related]
10. Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma. Klumpp TR; Mangan KF; Glenn LD; Malaspina DR; Cropper T; Mullaney M; Macdonald JS Bone Marrow Transplant; 1993 Oct; 12(4):337-45. PubMed ID: 7506091 [TBL] [Abstract][Full Text] [Related]
11. The role of high-dose chemotherapy in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Laport GF; Williams SF Semin Oncol; 1998 Aug; 25(4):503-17. PubMed ID: 9728600 [TBL] [Abstract][Full Text] [Related]
12. Autologous and allogeneic transplantation for aggressive NHL. Smith SM; Grinblatt D; van Besien K Cytotherapy; 2002; 4(3):223-40. PubMed ID: 12194719 [TBL] [Abstract][Full Text] [Related]
13. Longitudinal assessment of hematopoietic abnormalities after autologous hematopoietic cell transplantation for lymphoma. Bhatia R; Van Heijzen K; Palmer A; Komiya A; Slovak ML; Chang KL; Fung H; Krishnan A; Molina A; Nademanee A; O'Donnell M; Popplewell L; Rodriguez R; Forman SJ; Bhatia S J Clin Oncol; 2005 Sep; 23(27):6699-711. PubMed ID: 16170178 [TBL] [Abstract][Full Text] [Related]
14. A novel preparative regimen for autologous transplant in non-Hodgkin's lymphoma: long-term experience with etoposide and thiotepa. McCoy AG; Smith EP; Atkinson ME; Baranski B; Kahl BS; Juckett M; Mitchell T; Gangnon R; Longo WL Bone Marrow Transplant; 2004 Jan; 33(1):19-24. PubMed ID: 14704653 [TBL] [Abstract][Full Text] [Related]
15. High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease. Schiffman K; Buckner CD; Maziarz R; Maloney DG; Appelbaum FR; Press O; Gooley T; Holmberg L; Lilleby K; Clift R; Zuckerman N; Klarnet J; Weaver C; Chauncey T; Bensinger WI Biol Blood Marrow Transplant; 1997 Nov; 3(5):261-6. PubMed ID: 9450921 [TBL] [Abstract][Full Text] [Related]
16. Pre-transplant positron emission tomography (PET) using fluorine-18-fluoro-deoxyglucose (FDG) predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma. Cremerius U; Fabry U; Wildberger JE; Zimny M; Reinartz P; Nowak B; Schaefer W; Buell U; Osieka R Bone Marrow Transplant; 2002 Jul; 30(2):103-11. PubMed ID: 12132049 [TBL] [Abstract][Full Text] [Related]
17. Reduced intensity allogeneic stem cell transplantation for low grade non-Hodgkin's lymphoma. Morris EC; Mackinnon S Best Pract Res Clin Haematol; 2005 Mar; 18(1):129-42. PubMed ID: 15694189 [TBL] [Abstract][Full Text] [Related]
18. Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte antigen mismatch. Slack JL; Dueck AC; Fauble VD; Sproat LO; Reeder CB; Noel P; Khera N; Betcher JA; Klein JL; Leis JF; Adams RH Biol Blood Marrow Transplant; 2013 Aug; 19(8):1167-74. PubMed ID: 23664940 [TBL] [Abstract][Full Text] [Related]
19. Allogeneic stem cell transplantation with BEAM and alemtuzumab conditioning immediately after remission induction has curative potential in advanced T-cell non-Hodgkin's lymphoma. Czajczynska A; Günther A; Repp R; Humpe A; Schub N; Raff T; Nickelsen M; Schrauder A; Schrappe M; Kneba M; Gramatzki M Biol Blood Marrow Transplant; 2013 Nov; 19(11):1632-7. PubMed ID: 23850653 [TBL] [Abstract][Full Text] [Related]
20. Is hematopoietic cell transplantation still a valid option for mantle cell lymphoma in first remission in the chemoimmunotherapy-era? Chaudhary L; Kharfan-Dabaja MA; Hari P; Hamadani M Bone Marrow Transplant; 2013 Nov; 48(12):1489-96. PubMed ID: 23584438 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]